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Abstract 
Background: The modified Gompertz equation has been proposed to fit experimental data for direct current treated 
tumors when multiple-straight needle electrodes are individually inserted into the base perpendicular to the tumor 
long axis. The aim of this work is to evaluate the efficacy of direct current generated by multiple-electrode arrays on 
F3II mammary carcinoma that grow in the male and female BALB/c/Cenp mice, when multiple-straight needle elec-
trodes and multiple-pairs of electrodes are inserted in the tumor.
Methods: A longitudinal and retrospective preclinical study was carried out. Male and female BALB/c/Cenp mice, 
the modified Gompertz equation, intensities (2, 6 and 10 mA) and exposure times (10 and 20 min) of direct current, 
and three geometries of multiple-electrodes (one formed by collinear electrodes and two by pair-electrodes) were 
used. Tumor volume and mice weight were measured. In addition, the mean tumor doubling time, tumor regression 
percentage, tumor growth delay, direct current overall effectiveness and mice survival were calculated.
Results: The greatest growth retardation, mean doubling time, regression percentage and growth delay of the 
primary F3II mammary carcinoma in male and female mice were observed when the geometry of multiple-pairs of 
electrodes was arranged in the tumor at 45, 135, 225 and  325o and the longest exposure time. In addition, highest 
direct current overall effectiveness (above 66%) was observed for this EChT scheme.
Conclusions: It is concluded that electrochemical therapy may be potentially addressed to highly aggressive and 
metastic primary F3II murine mammary carcinoma and the modified Gompertz equation may be used to fit data of 
this direct current treated carcinoma. Additionally, electrochemical therapy effectiveness depends on the exposure 
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Highlights
• Multiple-pairs of electrodes are experimentally veri-
fied for the first time in the literature.
• Different geometries of multiple-electrodes and long 
exposure time can be addressed for electrochemical 
therapy.
• Modified Gompertz equation can be applied to any 
geometry of multiple-electrodes.
• Exposure time and electrode array geometries are 
included in the parameters of modified Gompertz 
equation.
Background
Antitumor effectiveness of the electrochemical therapy 
(EChT) with low-level direct current (DC) is demon-
strated in in vitro [1], preclinical [2] and clinical [3] stud-
ies. Nevertheless, it is poorly understood how tumor 
growth kinetics (TGK) is affected by DC application.
The modified Gompertz equation (MGE) to simulate 
and fit the different responses of experimental tumors 
after DC application is suggested by Cabrales et  al. [4], 
such as: disease progression (DP), stable disease (SD), 
partial response (PR) and complete response (CR). The 
data of Ehrlich and fibrosarcoma Sa-37 primary tumors 
[3] and highly aggressive and metastatic primary F3II 
mammary carcinoma [5] are adequately fitted with this 
equation. This validation of MGE is carried out for dif-
ferent values of DC intensity (i) and time of exposure of 
it  (texp), fixing the same electrode array geometry. Addi-
tionally, the stationary partial response [4], other findings 
[6] and how space–time distribution of the tumor density 
changes for each tumor response post-treatment [7] is 
revealed from the simulation of MGE. These theoretical 
and experimental results are valid when two or more col-
linear electrodes with alternating polarities inserted per-
pendicular to the larger diameter of the tumor are used.
In EChT, an important and interesting issue is to search 
electrode array geometries that maximizes the tumor 
volume with minimum damage to the organism. For 
this, multiple-straight needle electrodes inserted indi-
vidually in the tumor (MSNEII) are recommended for 
EChT: MSNEII inserted colineally along the major axis 
of the tumor  (MSNEIIc) [2, 3, 5, 6] or MSNEII inserted 
non-colineally anywhere of the tumor  (MSNEIInc) [8]. 
 MSNEIIc is the most used in preclinical [5] and clinical 
studies [3]; nevertheless, they have not given a defini-
tive solution to the cancer cure. Therefore, efforts are 
addressed to propose new  MSNEIInc.
The use of multiple-pairs of electrodes (MPE) for EChT 
treated tumors is suggested by Calzado et  al. [9]. High 
tumor damage percentages with the minimum damage 
to the organism are theoretically revealed for simulations 
of  MSNEIInc [8] and MPE [9], being noticeable for MPE. 
Nevertheless, the antitumor effectiveness and effects in 
the organism generated by these non-colineal electrode 
arrays are not reported in the literature. Additionally, we 
are not aware of the use of MGE to fit TGK treated with 
these multiple-electrode arrays. Therefore, the aim of this 
work is to evaluate the efficacy of direct current gener-
ated by multiple-electrode arrays on F3II mammary car-
cinoma that grow in the male and female BALB/c/Cenp 




A longitudinal and retrospective preclinical study was 
carried out between September–November 2017. The 
sarcomatoid mammary carcinoma cell line F3II that grow 
in BALB/c/Cenp mice was provided by the Centro de 
Inmunología Molecular (La Habana, Cuba). The charac-
teristics of F3II mammary carcinoma were reported in [5, 
10].
Stock F3II cells were conserved in minimal essen-
tial medium (MEM 41500, Gibco-BRL, Grand Island, 
NY) supplemented with 10% fetal bovine serum (Merck 
KGaA, Darmstadt, Germany), 2  mM glutamine (Merck 
KGaA, Darmstadt, Germany), 80  mg/ml Gentamy-
cin (Merck KGaA, Darmstadt, Germany), and 20  mg/
ml tetracycline (Merck KGaA, Darmstadt, Germany) in 
monolayer culture. For harvesting, cells were trypsinized 
using standard procedures. The cell viability was quan-
tified by Trypan blue dye exclusion test (Merck KGaA, 
Darmstadt, Germany) and over 95%. Cell count was car-
ried out under a microscope (model CX31, Olympus, 
Tokyo, Japan).
One hundred and sixty BALB/c/Cenp male and 
female mice (80 males and 80 females), 6–7  week old 
and 18–20 g weight were initially used. These mice were 
time, geometry of multiple-electrodes and ratio between the direct current intensity applied and the polarization cur-
rent induced in the tumor.
Keywords: Modified Gompertz equation, Tumor growth kinetics, Highly aggressive and metastatic primary F3II 
mammary carcinoma, Electrochemical therapy, Array of multiple-electrodes
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supplied by the Centro Nacional para la Producción de 
Animales de Laboratorio (CENPALAB, La Habana, 
Cuba). The experiment was conducted under a proto-
col approved by the Institutional Animal Care and Use 
Committee of CENPALAB (Registration number 16/17, 
code AETM0917, 17 May 2017), guidelines Animal Ethic 
Comission of República de Cuba and Council Direc-
tive 86/609/ECC of 24 November 1986, which followed 
guidelines for the welfare of animals in experimental 
neoplasia [11]. Each mouse was identified by dyeing with 
picric acid. Following the inoculation of tumor cells in 
the BALB/c/Cenp mice, daily meticulous clinical obser-
vations (including cage-side and handheld observations) 
were conducted throughout the study on all mice to 
monitor their general health states. Additionally, these 
observations were made to determine if significant clini-
cal abnormalities or death were present in mice from any 
of the experimental groups.
2x105 F3II sarcomatoid mammary carcinoma cells in 
0.2 ml of 0.9% NaCl (sodium chloride) in the right dor-
solateral region were inoculated in all mice. NaCl was 
supplied by the Laboratorios Biológicos Farmacéuticos 
(LABIOFAM, La Habana, Cuba). The latency time of 
local F3II tumor was monitored by palpation, which was 
done three times per week. The major and minor tumor 
diameters, in millimeters (mm), were measured with a 
venier caliper (Model 530-104, Mitutoyo, Tokyo, Japan) 
twice a week in order to record the evolution of each syn-
genic F3II tumor without sacrificing any animal. The vol-
ume of each individual tumor was computed by means of 
the formula V = πab2/6, in which a was the major diam-
eter of this tumor histological variety and b its minor 
diameter.
Mice were housed in clear standard polycarbon-
ate cages (1264C, TECNIPLAST, Varese, Italy) of 
206  mm2 × 12  cm (5 animals/cage) with autoclaved 
hard wood-shavings as bedding. They were maintained 
under automatically controlled environmental condi-
tions  (NODOREM®, Instituto Cubano de Investigaciones 
Digitales, La Habana, Cuba): temperature of 22 ± 2  °C, 
60–80% relative humidity, 12-h light/dark (light 7:00–
19:00) and a room air exchange of 12–18 times/h. Ani-
mals were provided Certified Rodent Diet EMO1004 
 (ALYCO®, CENPALAB, La Habana, Cuba) in granu-
lated form. Feed and water were sterilized by autoclaving 
(HS66, GETINGE, Gothenburg, Sweden) and available 
ad  libitum. Autoclaving was made at 120  °C for 60  min 
for water and at 120 °C for 20 min for feed and bedding. 
Animals bedding were daily changed.
Body weight of each mouse was determined with a 
precision balance  (Cubis® MSU, Sartorius, Goettingen, 
Germany) prior to inoculation of cells and then weekly. 
Furthermore, survival checks for morbidity and mortality 
were made twice per day. Any animal found dead or mor-
ibund was subjected to gross necropsy.
One configuration of  MSNEIIc and two of MPE were 
chosen from the simulations reported by Calzado et  al. 
[9].  MSNEIIc was formed by four collinear electrodes 
with alternating polarities inserted perpendicularly along 
the largest diameter of the tumor, named C-I. For C-I, 
electrodes 1 and 3 were positives whereas electrodes 2 
and 4 negatives (Fig. 1a).
The two configurations of MPE were formed by four 
electrode pairs inserted into the tumor. The first con-
figuration of MPE, named C-II, was formed by electrode 
pairs arranged to 45° (electrode pair 1–2), 135° (electrode 
pair 3–4), 225° (electrode pair 5–6) and 325° (electrode 
pair 7–8), as shown in Fig. 1b. For C-II, electrodes 1, 4, 5 
and 8 were positives whereas electrodes 2, 3, 6 and 7 neg-
atives. The second configuration of MPE, named C-III, 
was formed by electrode pairs arranged to 0° (electrode 
pair 1–2), 90° (electrode pair 3–4), 180° (electrode pair 
5–6) and 270° (electrode pair 7–8), as shown in Fig. 1c. 
For C-III, electrodes 2, 3, 5 and 8 were positives whereas 
electrodes 1, 4, 6 and 7 negatives.
For each pair of electrodes in each configuration of 
MPE, its angle was measured with respect to the largest 
tumor diameter counterclockwise. It was theoretically 
reported that the highest percentage of tumor damage 
was induced by C-II [9]. Therefore, C-II was the most 
used in this study.
The distance between electrodes was fixed at 0.5  cm 
for C-I, C-II and C-III. The AISI 316L austenitic stainless 
steel was chosed as electrode material for DC treatment 
(see details in [5]). The diameter of each electrode was 
0.7 mm and its length 68.5 mm.
After all electrodes were inserted, they were connected 
to the DC source. The  ONCOCED® B&E-01 device was 
used for EChT, which was applied when the initial vol-
ume of the tumors  (Vo) was approximately 0.5 cm3 (zero 
day). This tumor size was reached 31 days after their cells 
were inoculated in mice. DC intensity and voltage were 
continuously monitored during EChT application.
Once tumor cells were inoculated into mice, animals 
were randomly divided into eight experimental groups: 
a first control group, in which C-I was used but DC was 
not applied (CG1); a second control group, in which C-II 
was used but DC was not applied (CG2); a first group 
treated with 2  mA for 10  min and C-I (TG1); a second 
group treated with 6  mA for 20  min and C-II (TG2); 
a third group treated with 2  mA for 10  min and C-III 
(TG3); a fourth group treated with 2 mA for 10 min and 
C-II (TG4); a fifth group treated with 6  mA for 10  min 
and C-II (TG5) and a sixth group treated with 10 mA for 
10  min and C-II (TG6). These groups for females were 
defined CG1-F, CG2-F, TG1-F, TG2-F, TG3-F, TG4-F, 
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TG5-F and TG6-F whereas CG1-M, CG2-M, TG1-M, 
TG2-M, TG3-M, TG4-M, TG5-M and TG6-M for the 
males.
Each experimental group was initially formed by 10 
females and 10 males. The reduction (one of the criteria 
of the 3R [12, 13]) was taken into account to establish the 
number of animals, by experimental group.
Anesthesia before inserting the electrodes into the 
tumor was administered to mice. Anesthesia consisted 
of a mixture of 2.5 ml of Ketamine (Liorad, La Habana, 
Cuba), 1 ml of Atropine (LABIOFAM, La Habana, Cuba) 
and 2 ml of Diazepam (Empresa Laboratorios AICA del 
Grupo de las Industrias Biotecnólogica y Farmacéutica, 
La Habana, Cuba). This mixture was administered intra-
peritoneally (0.1 ml per 20 g of weight). The injection area 
was disinfected with 70% ethanol (Ministerio de Salud 
Pública, La Habana, Cuba), before and after administer-
ing anesthesia. All animals were placed in an isothermal 
blanket at 37 °C for recovery from anesthesia.
Control and treated groups were maintained under the 
same experimental conditions. Electrodes were inserted 
in all mice; nevertheless, the mice in the control groups 
did not receive DC. All mice were located on an iso-
thermal blanket at 37  °C for recovery from anesthesia. 
Daily evaluations of the clinical signs and symptoms, 
morbidity and mortality of each animal were made until 
the moment of euthanasia. Mice were bled by the fem-
oral vein, prior to anesthesia with diethyl ether (Merck, 
Darmstadt, Germany). After, these animals were sac-
rificed by cervical dislocation. Euthanasia of these mice 
was governed by the Standard Operating Procedure 
established in the CENPALAB (Edition 2003–2018).
Three kinetc parameters for each individual F3II 
mammary carcinoma were calculated, such as: regres-
sion percent (in %), mean doubling time (in days) and 







100% , where  Vmin was inter-
preted as the minimum tumor volume reached after DC 
application. The second parameter was defined as the 
time required for that this tumor type reaches a twofold 
increase of its initial volume. The third parameter was 
calculated by means of the ratio between mean doubling 
time of treated group and mean doubling time of its cor-
responding control group.
The individual tumor response after DC treatment (DP, 
SD, PR o CR) was documented in this study. Addition-
ally, overall EChT effectiveness (PR + CR) was reported, 
as suggested González et al. [5].
Modified Gompertz equation
The analysis of the entire TGK in the same mice and in two 
parts was suggested by González et  al. [5]: the first part 
Fig. 1 Schematic representation of different multiple-electrodes arrays inserted in a solid tumor. a Four collinear electrodes with alternating 
polarities inserted perpendicularly along the largest diameter of the tumor. Electrodes 1 and 3 (positive) and 2 and 4 (negative) were identified 
(C-I). b Four electrode pairs were arranged in the tumor to 45° (electrode pair 1–2), 135° (electrode pair 3–4), 225° (electrode pair 5–6) and 325° 
(electrode pair 7–8). Electrodes 1, 4, 5 and 8 were positives whereas electrodes 2, 3, 6 and 7 negatives (C-II). c Four electrode pairs were arranged in 
the tumor to 0° (electrode pair 1–2), 90° (electrode pair 3–4), 180° (electrode pair 5–6) and 270° (electrode pair 7–8). Electrodes 2, 3, 5 and 8 were 
positives whereas electrodes 1, 4, 6 and 7 negatives (C-III). Furthermore, the direction of insertion depth along the z-direction and the central plane 
represented by z = 0 were shown for each geometry of electrode array
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comprised from the moment of inoculation of the tumor 
cells in the host until the day that DC was applied, called 
 TGK1. The second part included from the moment of DC 
application until the day of sacrifice of the mice for ethical 
reasons [11], called  TGK2. This individual analysis of the 
TGK was done for each male and female. For this, MGE 
(Eq. 1) was used to fit experimental data for individual F3II 





where  V*(t), α, β, α*, i,  io and γ were used to denote the 
tumor volume at time t after DC treatment, the intrinsic 
growth rate of the tumor, the growth deceleration factor 
related to the endogenous antiangiogenesis processes, 
the modified tumor growth rate due to EChT application, 
the DC intensity, the polarization current and the first-
order exponential decay rate of the net effect induced in 
the solid tumor after the DC was removed, respectively. 
Dimensionless parameters  a1 and  a2 depended on the (i/
io) ratio [4–6, 14].
Interpolation of experimental data
Hermite interpolation was used to interpolate volume data 
for the individual F3II mammary carcinoma in each experi-
mental group. It was advised to know the values of α, β, γ 
and  io of this equation, as suggested in [5]. This was sug-
gested because the data used were not enough for their fit-
ting with Eq. (1).
Criteria for model assessment
Values and their estimation accuracies of α, β, γ and  io for 
the MGE were computed for each mouse by means of fol-
lowing criteria for model assessment [4–6, 14] 
(1)
































Dmáx = máx|Fi − Gi| ,
where  Dmax, RMSE, SSE, SE, r2 , r2a , PRESS and MPRESS 
were used to denote the maximum distance, Root Means 
Square Error, sum of squares of errors, standard error of 
the estimate, goodness-of-fit, adjusted goodness-of-fit 
coefficient of multiple determination, predicted residual 
error sum of squares and multiple predicted residual sum 
error of squares, respectively. SSE, SE, r2 , r2a , PRESS and 
MPRESS were chosed as fitting quality criteria. Least 
Sum of Squares of Errors was obtained when SSE was 
minimized in the Marquardt–Levenberg optimization 
algorithm.
RMSE and  Dmax were used to know how different the 
average TGK of each treated group respect its respective 
control group. In expressions of  Dmax and RMSE, M,  Fi 
and  Gi were defined as the number of interpolated data of 
tumor kinetics [tumor volume versus time plot], the i-th 
tumor volume of the control group that was chosen as 
the reference and the i-th tumor volume of the treated 
group to be compared with the reference group, respec-
tively. Nevertheless, in the expresions of SSE, SE, r2 , r2a , 
PRESS and MPRESS, V ∗j  was defined as the j-th meas-
ured tumor volume at discrete time  tj, j = 1, 2, …,  n1. V̂ ∗j  
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MGE.  n1 was the number of experimental points 
 (n1 = 11). The number of parameters was symbolized by 
k. The fitting was considered to be satisfactory when 





ignated as the estimated value of V ∗j  when MGE was 
obtained without the j-th observation. MPRESS removed 
the last n1 −m measurements. The model was fitted to 
the first m measured experimental points (m = 3, 4 or 5) 
and then from calculated model parameters the error 
between tumor volume estimated and measured values 
in the remaining n1 −m points was calculated [4–6, 14].
The analysis of the TGK in each experimental group 
was done following the same procedure reported in 
[5]. Fitting the full TGK (18–49  days post-inoculation) 
was performed for CG1-F, CG2-F, CG1-M and CG2-
M. For this, each time instant belonging to this range of 
days was subtracted 18 days so that the Eq.  (1) satisfied 
 V*(t = 0) = Vo (initial condition for  V*(t)). In this case, 
 Vo was the individual F3II mammary carcinoma vol-
ume reached at 18 days in each animal of CG1-F, CG2-
F, CG1-M and CG2-M. The tumor volume of 0.5  cm3 
was approximately observed at 31  days post-inocula-
tion (t = 0 for therapy), time in which DC was applied. 
The analysis per section of TGK was done in two parts 
 (TGK1 and  TGK2) for each animal and gender in all 
experimental groups.  TGK1 and  TGK2 comprised the 
time intervals from 18 to 31 and 31 to 49  days post-
inoculation, respectively. Each time instant in  TGK1 was 
subtracted 18 days whereas in  TGK2 31 days to fit each 
one of these two parts. This guaranteed that the MGE 
fulfilled  V*(t = 0) = Vo, where  Vo was the individual F3II 
mammary carcinoma volume reached at 18 and 31 days 
post-inoculation for  TGK1 and  TGK2, respectively. Once 
 TGK1 was fitted for each individual tumor, the values of 
α and β were introduced into the MGE to fit  TGK2, tak-
ing into account that the Eq.  (1) corresponded with the 
unperturbed Gompertz equation (DC intensity was equal 
to zero). This procedure permitted the analysis of the 
TGK to be conducted in the same mouse before and after 
EChT application, as suggested in [5].
Statistical criteria
The random distribution of mice by experimental group 
was done with the software of random numbers LAB-
TOOLS version 2.0, 1996 (Centro de Investigaciones y 
Evaluaciones Biológicas, Instituto de Farmacia y Alimen-
tos, La Habana, Cuba). Additionally, statistical analyses 
were carried out using Minitab 14 statistical software 
(Minitab for Windows, 2003, free software, National 
Institute of Standards and Technology, State University 
of Pensilvania, USA, https ://www.minit ab.com/es-mx/
produ cts/minit abs) for a confidence of 95%. Kolmogo-
rov–Smirnov test was used to determine the normal 
distribution of parameters. Levene’s test was used to 
know the homogeneity of variance. Kruskall-Wallis 
test and two-tailed Mann–Whitney test were applied 
to compare body mass and tumor volumes between the 
experimental groups, respectively. Logrank test was used 
for survival analysis, using free professional software 
GraphPad Prism (version 5.00, GraphPad Software, San 
Diego, CA). Both professional software programs worked 
on a PC (Intel Core i3 processor at 3.3 GHz) located at 
CENPALAB.
In order to fit each mouse growth curve Eq.  (1) was 
used. A computer program was implemented in the Mat-
lab software (version R2012b 64-bit, University Institute 
for Research in Mathematics and Applications, Univer-
sity of Zaragoza, Zaragoza, Spain) to calculate the tumor 
volume. In addition, the mean ± mean standard error of 
the parameters α, β, γ,  i0, SSE, SE, r2a , PRESS, MPRESS, 
RMSE and  Dmax were calculated from their individual 
values. In addition, the estimation errors of the param-
eters α, β, γ and  i0, named  eα,  eβ,  eγ and  ei0, respectively 
was computed. Mean standard error was calculated as 
(standard deviation)/ 
√
N , where N was the total number 
of determinations. These calculations were performed 
on a PC with an Intel(R) core processor™ i7-3770 at 
3.40 GHz with a Windows 10 operating system. All cal-
culations took approximately 10 min. In this study, mm 
were converted to cm (centimeters).
Results
Experimental results
Before the inoculation of tumoral cells, it were computed 
the average ± mean standard error of the weight of 80 
males (22.72 ± 1.03 g) and 80 females (21.27 ± 1.22 g). For 
80 female mice were estimated the average ± mean stand-
ard error of the latency time of the F3II mammary carci-
noma: 15.4 ± 3.3 days for CG1, 13.2 ± 2.2 days for CG2, 
12.0 ± 2.1 days for TG1, 11.6 ± 3.6 days for TG2, 13.2 ± 
3.2 days for TG3, 12.6 ± 4.1 days for TG4, 14.0 ± 3.8 days 
for TG5 and 15.0 ± 4.8 days for TG6, respectively. For 80 
male mice were calculated the average ± mean standard 
error of the latency time of the F3II mammary carci-
noma: 11.8 ± 4.2 days for CG1, 12.3 ± 3.0 days for CG2, 
11.0 ± 2.0 days for TG1, 12.0 ± 1.1 days for TG2, 11.5 ± 
2.0 days for TG3, 12.8 ± 4.5 days for TG4, 12.2 ± 3.9 days 
for TG5 and 11.0 ± 4.4 days for TG6, respectively. Statis-
tically significant differences were not observed between 
the F3II tumor latency time when experimental groups 
were compared, according to one tail Mann–Whitney U 
test (p > 0.05). It was observed that 100% of mice carried a 
tumor at the time of the DC application.
It was observed that 24.40% (39/160) of all mice 
died before DC application (31  days after the inocu-
lation): 28.80% (23/80) for females and 20.00 (16/80) 
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for males. These deaths were explained by three main 
reasons. Firstly, multiple metastasic nodules in lungs 
(19.38% = 31/160) were observed in CG1-F (3), CG1-M 
(4), CG2-F (3), CG2-M (4), TG2-F (2), TG3-F (4), TG4-F 
(1), TG5-F (4), TG5-M (1), TG6-F (3) and TG6-M (2). 
This finding was confirmed in the histological study of 
organs. Secondly, animal deaths (2.50% = 4/160) in TG2-F 
(2), TG2-M (1) and TG4-F (1) were seen after anesthesia 
administration. Thirdly, euthanasia (2.50% = 4/160) was 
carried out in mice of TG2-M (2) and TG6-M (2) due to 
very large tumors (tumor volumes ≥ 2 cm3).
It was calculated the average ± mean standard error 
of the mice weight for 64 males (25.59 ± 1.05  g) and 57 
females (23.31 ± 1.06  g) before DC application. The 
weight of male mice was significantly higher than that 
female mice (Fig. 2). Except for TG2 in both genders, sta-
tistically significant differences between weights of male 
and female mice, in each experimental group, were not 
observed (p > 0.05). In this group, from the beginning of 
the experiment, the weight was significantly lower, with 
regard to the rest of the experimental groups (p = 0.0012), 
according to the statistical evaluation for ANOVA test 
(Fig. 2).
It was reported that 13.48% (19/141) of mice died after 
EChT application. These deaths were observed in 84.21% 
(16/19) of mice (six females and 10 males) at the first 72 h 
after DC application and 15.79% (3/19) after 72  h post-
treatment (two females and one male). All these deaths 
were confirmed by histological study of organs.
At the first 72  h after DC application, deaths were 
observed in six mice of control groups (two of CG1-F, 
one of CG1-M, two of CG2-F and one of CG2-M) and 
five mice of DC treated groups (one of TG2-M, one of 
TG3-M, one of TG4-F, one of TG5-M and one of TG6-
F) due to multiple metastatic nodules in lungs. Other 
five mice deaths were documented by alterations in their 
organs: heart damage (mechanical rupture by insertion 
of electrodes pair) was observed in one mouse of TG5-
M, liver damage was seen in one mouse of TG2-M and 
damages in both liver and kidney organs were perceived 
in one mouse of TG3-M and two mice of TG4-M. Addi-
tionally, deaths by lung metastasis (one mouse of TG3-F 
and one mouse of TG5-F) and damages in both liver and 
kidney organs (one mouse of TG6-M) were reported 72 h 
post-treatment.
As a result of deaths mentioned-above, all experimen-
tal results for 76.250% (122/160) of mice were reported 
in this study: 66.25% (53/80) of males and 61.25% (49/80) 
of females. The gain of corporal weight of mice BALB/c/
Cenp was shown in Table 1 for days 7, 14, 21, 28, 42 and 
Fig. 2 Mean ± mean standard error of corporal weight of the mice BALB/c/Cenp versus days post-inoculation of the tumoral cells F3II. a Males. b 
Females. The legends of the experimental groups were defined in Methods
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49 after inoculation, by experimental group and gender. 
In this table was revealed that there was not exist statis-
tically significant differences (p > 0.05) when the treated 
groups were compared with their respective groups con-
trol, for each gender, according to ANOVA test.
The mean ± mean standard error of the tumor regres-
sion percentages were documented for each experimen-
tal group and gender: 62.33 ± 28.45% for TG1-F (N = 10), 
70.67 ± 25.48% for TG1-M (N = 10), 74.00 ± 26.16% 
for TG2-F (N = 6), 77.43 ± 28.08% for TG2-M (N = 5), 
44.50 ± 23.44% for TG3-F (N = 5), 61.75 ± 27.72% for 
TG3-M (N = 8), 36.33 ± 29.54% for TG4-F (N = 7), 
45.67 ± 28.62% for TG4-F (N = 8), 30.33 ± 27.77% for 
TG5-F (N = 5), 37.33 ± 21.42% for TG5-M (N = 7), 61.00 
± 29.90% for TG6-F (N = 6) and 57.33 ± 29.43% for 
TG6-M (N = 5). The highest regression percentages were 
observed for TG2-F and TG2-M.
The quantity of DC treated F3II mammary carcinomas 
distributed for each tumor response type (PD, SD, PR 
or CR) and EChT global effectiveness were displayed in 
Table  2, by experimental group and gender. The higher 
effectiveness of the DC was observed for the TG2-F 
(66.6%) and TG2-M groups (80%) and the lowest for both 
genders in the TG4 and TG5 groups. Animals that died 
before treatment were not included in these percentages. 
The tumor remission was not observed in the tumors of 
CG1-F, CG2-F, CG1-M and CG2-M, which ruled out the 
induction of spontaneous remissions of F3II carcinoma.
The mean ± standard error of the doubling time of the 
F3II mammary carcinoma (in days) were presented in 
Table  3 by each gender and experimental group. It was 
also observed that in the control groups of both gen-
ders, this kinetics parameter was lower than that in the 
treated groups. Additionally, an increase in the doubling 
time of this malignat tumor of all treated groups was 
induced by DC action, except in TG4-F. This increase was 
statistically significant (p = 0.0497) in the TG2-F, TG2-
M, TG3-F and TG6-F groups, according to the one-tail 
Mann–Whitney U test.
On the other hand, the values of tumor growth delay 
were computed for TG1-F (1.08  days with N = 100), 
TG1-M (0.93 with N = 10), TG2-F (1.82 days with N = 6), 
TG2-M (2.00  days; N = 5), TG3-F (1.93  days; N = 5), 
TG3-M (2.19  days; N = 8), TG4-F (0.79  days; N = 7), 
TG4-M (1.94  days; N = 8), TG5-F (1.11  days; N = 5), 
TG5-M (1.69 days; N = 7), TG6-F (3.21 days; N = 6) and 
TG6-M (1.77  days; N = 5). The higher tumor growth 
delay was observed in TG2-F and TG2-M when  MSNEIIc 
was used. Additionally, the higher tumor growth delays 
were seen in TG6-F and TG3-M, being noticeable for 
TG3-M.
Physiological ulcerations were observed in the tumors 
of the control groups and DC treated groups. Further-
more, fibrosis of hard texture (with aspect of scab) were 
observed after EChT applicaction in some tumors of each 
treated group.
Table 1 Mean ± mean standard error of  the  body weight gain of  mice after  direc current application by  group 
experimental and gender
G, N, F and M were identified as the gender, number of mice by experimental group and gender, female gender and male gender, respectively. The legend of each 
experimental group was defined in the topic Methods
Groups G Gain of corporal weight (in g)
7 14 21 28 42 49
CG1 M (N = 5) 0.62 ± 0.29 1.96 ± 0.36 2.38 ± 0.20 3.22 ± 0.43 4.58 ± 0.88 4.60 ± 1.22
F (N = 5) 0.42 ± 0.18 1.07 ± 0.59 0.59 ± 0.50 1.34 ± 0.47 3.30 ± 1.03 3.30 ± 1.55
CG2 M (N = 5) 0.72 ± 0.55 2.10 ± 0.80 2.56 ± 0.64 1.63 ± 1.70 5.04 ± 0.43 5.60 ± 0.94
F (N = 5) 0.38 ± 0.24 0.80 ± 0.49 0.60 ± 0.38 0.64 ± 0.22 2.75 ± 0.72 3.84 ± 0.88
TG1 M (N = 10) 0.30 ± 0.51 1.62 ± 0.42 1.64 ± 0.43 2.78 ± 0.57 3.50 ± 0.74 5.29 ± 0.54
F (N = 10) 0.55 ± 0.19 0.44 ± 0.36 0.44 ± 0.36 0.93 ± 0.20 1.72 ± 0.52 2.88 ± 0.34
TG2 M (N = 5) 0.45 ± 0.43 1.46 ± 0.53 2.66 ± 0.65 2.24 ± 0.77 2.67 ± 0.44 3.53 ± 0.45
F (N = 6) 1.29 ± 0.16 0.95 ± 0.12 1.40 ± 0.17 1.57 ± 0.20 1.47 ± 0.18 2.47 ± 0.31
TG3 M (N = 8) 0.61 ± 0.47 1.64 ± 0.14 2.52 ± 0.77 2.75 ± 0.25 3.65 ± 0.46 5.83 ± 0.46
F (N = 5 − 0.07 ± 0.42 0.60 ± 0.35 0.47 ± 0.34 0.75 ± 0.43 2.53 ± 0.43 3.05 ± 0.34
TG4 M (N = 8) 0.99 ± 0.13 2.12 ± 0.40 1.12 ± 1.15 3.43 ± 0.53 3.62 ± 0.77 5.70 ± 0.86
F (N = 7) 0.49 ± 0.15 0.66 ± 0.48 0.75 ± 0.16 1.05 ± 0.37 3.50 ± 0.93 4.59 ± 1.09
TG5 M (N = 7) − 0.59 ± 1.82 1.54 ± 0.63 2.41 ± 0.32 3.68 ± 0.43 2.60 ± 0.46 3.97 ± 0.41
F (N = 5) 0.50 ± 0.24 0.62 ± 0.35 1.29 ± 0.31 1.65 ± 0.52 1.87 ± 1.02 3.37 ± 0.74
TG6 M (N = 5) 0.51 ± 0.03 1.72 ± 0.27 1.30 ± 0.24 2.90 ± 0.18 4.81 ± 0.29 6.17 ± 0.25
F (N = 6) 0.20 ± 0.24 0.95 ± 0.27 0.53 ± 0.27 0.83 ± 0.60 0.94 ± 0.46 2.13 ± 1.22
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In Fig.  3 was showed the temporal behavior of the 
tumor volume after the inoculation of the tumor cells in 
the host by each experimental group for males (Fig. 3a) 
and females (Fig. 3b). The growth of primary F3II mam-
mary carcinoma of the CG1-F and CG2-F was greater 
than that of the CG1-M and CG2-M, respectively. This 
finding was explained in [5]. In addition, a delay in the 
growth of this tumor histological variety was observed in 
each treated group with respect to that of their respective 
control groups for females and males.
In Fig.  4 was displayed the overall survival percent-
ages of females (Fig.  4a) and males (Fig.  4b) for each 
experimental group. A significant decrease in the over-
all survival of the CG1-F mice with respect to TG1-F 
(p = 0.0142) was documented when the Logrank test was 
used. In addition, it was reported a significant decrease 
of this parameter in the TG2-M and TG6-M groups 
(p = 0.0321) when compared to CG1-M and CG2-M, 
respectively. Additionally, the mice survival in TG2-M 
lower than that in CG1-M was revealed. This finding 
was also observed in TG3-M, TG4-M and TG6-M with 
respect to CG2-M. 100% of the mice survival in TG1-M 
and TG1-F was reported.
Very larger tumor volumes (above 3  cm3) at 49  days 
after inoculation were observed in the majority of mice 
in all experimental group, except in TG2-F and TG2-M. 
Consequently, all mice were sacrified in order to perform 
ethical aspects in laboratory animals (tumor burden did 
not exceed 10% of the host animal’s normal body weight), 
as reported in [5, 11].
Table 2 Different F3II tumor response types after  electrochemical therapy application by  experimental group 
and gender
N was defined as the total number of mice carrying the F3II mammary carcinoma in each experimental group. The percentage (in brackets) by tumor response after 
electrochemical therapy was represented by  %. PD, SD, PR and CR were denoted as progressive disease, stable disease, partial response and complete response, 
respectively. The legend of each experimental group was defined in the topic Methods




PD (%) SD (%) PR (%) CR (%)
TG1 F (N = 10) 1 (10.0) 4 (40.0) 5 (50.0) 0 (0.0) 5 (50.0)
M (N = 10) 1 (10.0) 3 (30.0) 6 (60.0) 0 (0.0) 6 (60.0)
TG2 F (N = 6) 1 (16.7) 1 (16.7) 4 (66.6) 0 (0.0) 4 (66.6)
M (N = 5) 0 (0.0) 1 (20.0) 4 (80.0) 0 (0.0) 4 (80.0)
TG3 F (N = 5) 1 (20.0) 1 (10.0) 3 (30.0) 0 (0.0) 3 (30.0)
M (N = 8) 2 (25.0) 3 (25.0) 4 (50.0) 0 (0.0) 4 (50.0)
TG4 F (N = 7) 2 (28.6) 3 (42.8) 2 (28.6) 0 (0.0) 2 (28.6)
M (N = 8) 2 (25.0) 3 (37.5) 4 (50.0) 0 (0.0) 4 (50.0)
TG5 F (N = 5) 1 (20.0) 1 (20.0) 2 (40.0) 0 (0.0) 2 (40.0)
M (N = 7) 1 (14.4) 3 (42.8) 3 (42.8) 0 (0.0) 3 (42.8)
TG6 F (N = 6) 1 (16.7) 2 (33.3) 3 (50.0) 0 (0.0) 3 (50.0)
M (N = 5) 1 (20.0) 2 (40.0) 2 (40.0) 0 (0.0) 2 (40.0)
Table 3 Mean ± mean standard error of  the  tumor 
doubling time before  and  after 31  days post-inoculation 
by experimental group and gender
The number of mice by gender in each experimental, female gender and male 
gender were represented by N, F and M, respectively. aStatistically significant 
differences (p = 0.0497) according to one tail Mann–Whitney U test. The legend 
of each experimental group was defined in the topic Methods
Groups Gender Doubling time of the F3II mammary 
carcinoma (days)
Before DC treatment After DC treatment
CG1 M (N = 5) 4.33 ± 0.92 6.00 ± 2.20
F (N = 5) 4.27 ± 1.97 6.50 ± 1.06
CG2 M (N = 5) 3.60 ± 0.93 3.20 ± 0.86
F (N = 5) 2.00 ± 1.51 4.80 ± 1.02
TG1 M (N = 10) 1.60 ± 0.59 5.60 ± 1.80
F (N = 10) 4.25 ± 1.22 7.00 ± 1.18
TG2 M (N = 5) 7.20 ± 2.35 11.20 ± 2.95a
F (N = 6) 5.17 ± 0.83 12.75 ± 2.35a
TG3 M (N = 8) 5.17 ± 1.28 7.00 ± 1.93
F (N = 5 3.75 ± 1.25 9.25 ± 2.02a
TG4 M (N = 8) 5.40 ± 1.72 6.20 ± 2.45
F (N = 7) 5.80 ± 1.24 3.80 ± 0.58
TG5 M (N = 7) 3.80 ± 0.37 5.40 ± 1.16
F (N = 5) 3.75 ± 1.38 5.33 ± 1.45
TG6 M (N = 5) 3.50 ± 2.51 5. 66 ± 4.01
F (N = 6) 5.00 ± 1.45 15.40 ± 0.98a
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Analysis of interpolated data
Mathematical modeling was suggested to ana-
lyse TGK once finished the experimental part of this 
study. Although in Fig.  3 were shown larger mean 
standard errors of tumor volumes, fitting TGK of 21 
(21/122 = 17.21%) mice (eight females and 13 males) 
were not made because their tumor volumes were higher 
and equal than 2 cm3, taken into account ethical aspects 
in laboratory animals above-mentioned. Consequently, 
80 BALB/c/Cenp mice (40 males and 40 females) were 
included to fit individual TGK. Each experimental group 
was formed by 5 females and 5 males.
The averages and mean standard errors of α, β,  eα,  eβ, 
SSE, SE, PRESS, MPRESS, RMSE and  Dmax obtained from 
the individual analysis of  TGK1, by experimental group, 
were shown in Tables  4 and 5 for females and males, 
respectively. It was reported that females showed higher 
values α and lower β than those for males, which corrob-
orated that TGK was faster in females than in males, as 
in [5]. Additionally, α* decreased respect to α in all DC 
treated groups. Nevertheless, β did not change signifi-
cantly before and after DC application (Tables 4 and 5).
In Table 6 was showed the averages and mean standard 
errors of  i0, γ,  ei0,  eγ, SSE, SE, r2a , PRESS, MPRESS, RMSE 
and  Dmax obtained from the individual analysis of  TGK2, 
for females, by experimental group. These values were 
also shown for males and each group (Table 7). In addi-
tion, the values of the (i/i0) ratio were shown in Tables 6 
and 7.
For female, the higher values of the (i/i0) ratio were 
observed in TG2-F, TG6-F and TG3-F whereas the lower 
values of γ in TG2-F and TG6-F. These findings were 
noticeable for TG2-F (Table  6). For male, the higher 
values of the (i/i0) ratio were observed in TG2-M and 
TG6-M whereas the lower value of γ in TG2-M. These 
findings were noticeable for TG2-M (Table 7).
Tables  4, 5, 6, 7 showed that the average values of r2a 
were close to one and the values of SSE, SE, PRESS, 
MPRESS (for m = 3), RMSE and  Dmax were close to 
zero. MPRESS values for m = 3, 4 and 5 were similar in 
each experimental group and for each gender, as in [4, 
5]. Therefore, in this study, these MPRESS values were 
reported for m = 3.
Discussion
The minus sign of the weight gain in TG3-F and TG5-M 
at 7  days post-inoculation is interpreted as a decrease 
of this variable. Nevertheless, weight gain in these two 
groups increases after 7 days. Non significant differences 
in weight gain suggests that anesthesia, electrode inser-
tion and applied treatment do not affect this parameter in 
Fig. 3 Mean ± mean standard error of the tumor volume against post-inoculation days of F3II tumor cells. a Males BALB/c/Cenp mice (M). b 
Females BALB/c/Cenp mice (F). Legends of each experimental group were defined in the Experiment subsection
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Fig. 4 Survival versus days after inoculation of F3II cells in mice BALB/c/Cenp, by experimental group and gender. a Females. b Males. CG1 (first 
control group, in which C-I was used but DC was not applied). CG2 (second control group, in which C-II was used but DC was not applied). TG1 
(first group treated with 2 mA for 10 min and C-I). TG2 (second group treated with 6 mA for 20 min and C-II). TG3 (third group treated with 2 mA for 
10 min and C-III). TG4 (fourth group treated with 2 mA for 10 min and C-II). TG5 (fifth group treated with 6 mA for 10 min and C-II). TG6 (sixth group 
treated with 10 mA for 10 min and C-II). C-I was formed by four collinear electrodes with alternating polarities inserted perpendicularly along the 
largest diameter of the tumor (electrodes 1 and 3 were positives whereas electrodes 2 and 4 negatives), as shown in Fig. 1a. C-II were formed by four 
electrode pairs inserted into the tumor to 45° (electrode pair 1–2), 135° (electrode pair 3–4), 225° (electrode pair 5–6) and 325° (electrode pair 7–8), 
as shown in Fig. 1b. For C-II, electrodes 1, 4, 5 and 8 were positives whereas electrodes 2, 3, 6 and 7 negatives. C-III were formed by four electrode 
pairs arranged into the tumor to 0° (electrode pair 1–2), 90° (electrode pair 3–4), 180° (electrode pair 5–6) and 270° (electrode pair 7–8), as shown in 
Fig. 1c. For C-III, electrodes 2, 3, 5 and 8 were positives whereas electrodes 1, 4, 6 and 7 negatives
Table 4 Mean ± mean standard error of parameters obtained from fitting of  TGK1 for female groups
* 0.0031 ± 0.0002,**0.0012 ± 0.0001.  TGK1 was the first part of the unperturbed and direct current perturbed F3II tumor growth kinetic. The variable α was the intrinsic 
growth rate of the tumor and  eα its estimation error. The variable β was the growth decelation factor and  eβ its estimation error. The maximum distance, root means 
square error, sum of squares of errors, standard error of the estimate, adjusted goodness-of-fit coefficient of multiple determination, predicted residual error sum of 
squares and multiple predicted residual sum error of squares parameters were represented by  Dmax, RMSE, SSE, SE, r
2
a , PRESS and MPRESS (for m = 3), respectively. 
Legends of CG1-F, CG2-F, TG1-F, TG2-F, TG3-F, TG4-F, TG5-F and TG6-F were defined in Experiment subsection
Parameters Experimental groups
CG1-F CG2-F TG1-F TG2-F TG3-F TG4-F TG5-F TG6-F
α  (days−1) 0.462 ± 0.044 0.490 ± 0.189 0.462 ± 0.044 0.490 ± 0.189 0.490 ± 0.189 0.490 ± 0.189 0.490 ± 0.189 0.490 ± 0.189
α*  (days−1) – – 0.167 ± 0.019 0.300 ± 0.057 0.224 ± 0.033 0.197 ± 0.027 0.206 ± 0.014 0.187 ± 0.049
β  (days−1) 0.024 ± 0.026 0.013 ± 0.060 0.009 ± 0.005 0.055 ± 0.029 0.026 ± 0.014 0.023 ± 0.004 0.001 ± 0.001 0.016 ± 0.016
eα  (days
−1) 0.011 ± 0.003 0.008 ± 0.070 0.098 ± 0.075 0.073 ± 0.061 0.012 ± 0.005 0.015 ± 0.007 0.089 ± 0.057 0.037 ± 0.016
eβ  (days
−1) 0.003 ± 0,000* 0.007 ± 0.002 0.006 ± 0.001 0.051 ± 0.006 0.001 ± 0.000** 0.008 ± 0.001 0.009 ± 0.003 0.015 ± 0.001
SSE  (cm3) 0.016 ± 0.007 0.011 ± 0.002 0.113 ± 0.032 0.154 ± 0.051 0.613 ± 0.493 0.222 ± 0.107 0.079 ± 0.026 0.712 ± 0.248




0.994 ± 0.002 0.964 ± 0.015 0.977 ± 0.006 0.956 ± 0.007 0.980 ± 0.010 0.938 ± 0.038 0.964 ± 0.019 0.958 ± 0.013
PRESS  (cm3) 0.001 ± 0.001 0.002 ± 0.001 0.012 ± 0.003 0.018 ± 0.006 0.029 ± 0.018 0.035 ± 0.022 0.016 ± 0.012 0.149 ± 0.063
MPRESS  (cm3) 0.001 ± 0.001 0.002 ± 0.001 0.012 ± 0.003 0.018 ± 0.006 0.029 ± 0.018 0.035 ± 0.023 0.016 ± 0.012 0.151 ± 0.064
RMSE  (cm3) 0.018 ± 0.005 0.017 ± 0.002 0.026 ± 0.003 0.029 ± 0.005 0.048 ± 0.024 0.032 ± 0.009 0.022 ± 0.004 0.060 ± 0.015
Dmax  (cm
3) 0.034 ± 0.010 0.038 ± 0.010 0.054 ± 0.008 0.059 ± 0.011 0.110 ± 0.047 0.074 ± 0.023 0.054 ± 0.004 0.118 ± 0.031
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BALB/c/Cenp mice carrying the F3II carcinoma for both 
genders.
Different findings of this study corroborate those 
reported in [5], such as male mice weights higher than 
those female mice; the weight gain over time of all 
BALB/c/Cenp mice; the variability of the F3II mammary 
carcinoma latency time; BALB/c/Cenp mouse suitables 
for this tumor histological variety (tumor grows in 100% 
of BALB/c/Cenp mice); cell line highly invasive and met-
astatic and greater growth delay. Regression percentage 
and doubling time of this DC treated tumor type.
The greatest growth delay, mean doubling time, regres-
sion percentage of the F3II carcinoma and DC overall 
effectiveness in TG2-F and TG2-M confirm that this 
tumor histological variety should be treated with low DC 
intensities and longer exposure time, as suggest in [5]. 
Table 5 Average ± mean standard error of parameters obtained from fitting of  TGK1 for male groups
* 0.0075±0.0006, **0.0021 ± 0.0003.  TGK1 was the first part of the unperturbed and direct current perturbed F3II tumor growth kinetic. The variable α was the intrinsic 
growth rate of the tumor and  eα its estimation error. The variable β was the growth decelation factor and  eβ its estimation error. The maximum distance, root means 
square error, sum of squares of errors, standard error of the estimate, adjusted goodness-of-fit coefficient of multiple determination, predicted residual error sum of 
squares and multiple predicted residual sum error of squares were represented by parameters  Dmax, RMSE, SSE, SE, r
2
a , PRESS and MPRESS (for m = 3), respectively. 
Legends of CG1-F, CG2-F, TG1-F, TG2-F, TG3-F, TG4-F, TG5-F and TG6-F were defined in Experiment subsection
Parameters Experimental groups
CG1-M CG2-M TG1-M TG2-M TG3-M TG4-M TG5-M TG6-M
α  (days−1) 0.426 ± 0.059 0.422 ± 0.031 0.426 ± 0.059 0.422 ± 0.031 0.422 ± 0.031 0.422 ± 0.031 0.422 ± 0.031 0.422 ± 0.031
α*  (days−1) – – 0.226 ± 0.107 0.303 ± 0.051 0.201 ± 0.046 0.174 ± 0.049 0.244 ± 0.034 0.202 ± 0.087
β  (days−1) 0.034 ± 0.022 0.049 ± 0.016 0.059 ± 0.044 0.078 ± 0.050 0.017 ± 0.017 0.058 ± 0.046 0.028 ± 0.010 0.014 ± 0.014
eα  (days
−1) 0.021 ± 0.050 0.011 ± 0.070 0.098 ± 0.057 0.037 ± 0.061 0.010 ± 0.003 0.015 ± 0.007 0.089 ± 0.057 0.037 ± 0.016
eβ  (days
−1) 0.001 ± 0.000 0.007 ± 0.000* 0.002 ± 0.001 0.015 ± 0.002 0.002 ± 0.000** 0.009 ± 0.001 0.009 ± 0.003 0.051 ± 0.008
SSE  (cm3) 0.184 ± 0.068 0.055 ± 0.032 0.147 ± 0.079 0.053 ± 0.014 0.300 ± 0.238 0.334 ± 0.219 0.072 ± 0.023 0.138 ± 0.095




0.979 ± 0.003 0.985 ± 0.007 0.964 ± 0.016 0.980 ± 0.005 0.922 ± 0.019 0.978 ± 0.008 0.991 ± 0.005 0.965 ± 0.007
PRESS  (cm3) 0.030 ± 0.016 0.004 ± 0.002 0.023 ± 0.019 0.003 ± 0.001 0.018 ± 0.010 0.036 ± 0.020 0.007 ± 0.003 0.004 ± 0.003
MPRESS  (cm3) 0.030 ± 0.016 0.004 ± 0.002 0.023 ± 0.019 0.003 ± 0.001 0.018 ± 0.010 0.036 ± 0.020 0.007 ± 0.003 0.005 ± 0.003
RMSE  (cm3) 0.061 ± 0.015 0.032 ± 0.011 0.026 ± 0.008 0.017 ± 0.003 0.061 ± 0.031 0.036 ± 0.015 0.019 ± 0.004 0.028 ± 0.011
Dmax  (cm
3) 0.137 ± 0.037 0.064 ± 0.023 0.061 ± 0.020 0.035 ± 0.008 0.139 ± 0.065 0.069 ± 0.027 0.036 ± 0.008 0.065 ± 0.009
Table 6 Mean ± mean standard error of  parameters obtained from  fitting of   TGK2 for  direct current treated female 
groups
* 0.016 ± 0.0001, **0.054 ± 0.0005, ***0.093 ± 0.0002, +0.004 ± 0.0001 and ++0.007 ± 0.0006.  TGK2 was the second part of the direct current perturbed F3II tumor 
growth kinetic. The variable  i0 was the polarization current and  ei0 its estimation error. The variable γ was the exponential decay ratio and  eγ its estimation error. The 
maximum distance, root means square error, sum of squares of errors, standard error of the estimate, adjusted goodness-of-fit coefficient of multiple determination, 
predicted residual error sum of squares and multiple predicted residual sum error of squares were identified by parameters  Dmax, RMSE, SSE, SE, r
2
a , PRESS and MPRESS 
(for m = 3), respectively. Legends of TG1-F, TG2-F, TG3-F, TG4-F, TG5-F and TG6-F were defined in Experiment subsection
Parameters Experimental groups
TG1-F TG2-F TG3-F TG4-F TG5-F TG6-F
i0 (mA) 1.561 ± 0.057 4.061 ± 0.238 1.413 ± 0.048 1.569 ± 0.062 4.415 ± 0.299 6.942 ± 0.485
i/i0 1.333 1.477 1.415 1.275 1.359 1.440
γ  (days−1) 17.742 ± 6.769 12.890 ± 4.379 26.291 ± 11.321 36.567 ± 8.088 49.672 ± 18.227 13.672 ± 5.227
ei0  (days
−1) 0.016 ± 0.000* 0.043 ± 0.004 0.054 ± 0.000** 0.093 ± 0.000*** 0.021 ± 0.006 0.034 ± 0.003
eγ  (days
−1) 0.056 ± 0.002 0.004 ± 0.000+ 0.921 ± 0.083 0.015 ± 0.004 0.023 ± 0.005 0.007 ± 0.000++
SSE  (cm3) 0.115 ± 0.052 0.068 ± 0.024 0.522 ± 0.268 0.392 ± 0.130 0.226 ± 0.081 0.226 ± 0.081
SE  (cm3) 0.040 ± 0.013 0.036 ± 0.009 0.082 ± 0.034 0.087 ± 0.017 0.068 ± 0.010 0.068 ± 0.010
RMSE  (cm3) 0.039 ± 0.013 0.034 ± 0.008 0.080 ± 0.033 0.084 ± 0.017 0.065 ± 0.010 0.065 ± 0.010
PRESS  (cm3) 0.017 ± 0.013 0.014 ± 0.007 0.103 ± 0.072 0.098 ± 0.048 0.021 ± 0.008 0.021 ± 0.008




0.997 ± 0.001 0.989 ± 0.006 0.996 ± 0.002 0.991 ± 0.004 0.994 ± 0.002 0.994 ± 0.002
Dmax  (cm
3) 0.085 ± 0.032 0.065 ± 0.015 0.182 ± 0.068 0.175 ± 0.030 0.158 ± 0.043 0.158 ± 0.043
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These findings may suggest that in TG2-F and TG2-M 
are induced higher tumor damage percentages due to 
DC cytotoxic action, as reported experimentally in [1–3, 
5, 15]. DC cytotoxic action is explained by induction of 
toxic products into the tumor from the electrochemical 
reactions around the electrodes during its application [1–
3, 16–18] and the immune system activation [5].
High tumor damage percentages by DC action sup-
poses that φ (by apoptosis and/or necrosis induced 
around electrodes) is increased and GF is decreased, 
where φ and GF are cell loss factors and tumor growth 
fraction, respectively. A a result, the tumor mean 
doubling time (DT) increases, according to the Steel 
equation ( DT = Tc ln 2
/
(1− ϕ) ln(1+ GF) ) with 
GF = Ncc
/
(Ncc + Nn−cc) , where  Tc,  Ncc, and  Nn-cc are 
defined the cell cycle time, number of tumor cells in the 
cell cycle and the number of tumor cells that are not in 
the cell cycle, respectively [19]. Nevertheless, the quick 
growth of the tumor volume 40  days after inoculation 
may be explained because GF increases quickly because 
 Ncc (due to the fast process of cell duplication) and/or 
 Nn-cc (number of non-divisible cells enter rapidly to the 
cell cycle) increase, resulting in a decrease of DT. In this 
case, metastasis induced by DC is discarded taking into 
account results reported by Zhou et al. [20].
For the case of unperturbed F3II mammary carcinoma, 
DT is shorter because φ (apoptosis, necrosis, exfoliation 
and metastasis, mainly metastasis) and GF (quick cellular 
multiplication) increase, confirming that this tumor his-
tological variety is highly aggressive and metastatic. This 
may be related to the finding that the high BALB/c/Cenp/
mice death percentage is mainly due to the metastasis. As 
a result, EChT should be applied with care in this tumor 
histological variety.
González et  al. [5] suggest that the highly aggressive 
and metastatic primary F3II mammary carcinoma has a 
major electrical conductivity and therefore its high sen-
sitivity to DC action. This may explain, in part, the six 
mice deaths during and after DC application. Irrevers-
ible alterations in liver and kidney organs may be due to 
the metabolic burden of the products of tumor rupture, 
as documentd in [5]. Additionally, high amount of heat 
induced in the tumor by MPE should not be discarded, 
as predict simulations reported in [9]. Therefore, EChT 
should be also applied with care in this tumor histologi-
cal variety.
Unlike [5], CR is not observed in any DC treated tumor 
in this study. Nevertheless, higher values of the over-
all EChT effectiveness suggest that this therapy may be 
addressed to highly aggressive and metastatic primary 
tumors, as the F3II mammary carcinoma. Despite this, it 
should not be categorically affirmed that EChT is safe in 
laboratory animals, as reported in [5].
Larger mean standard errors observed in all experi-
mental groups may be explained from biological individ-
uality of each mouse, physiological ulcerations in control 
and DC treated tumors, the diversity of response of each 
tumor after EChT application and the fibrosis in some 
DC treated tumors. These errors are marked for tumor 
volumes higher than 1.5  cm3 because their borders are 
very irregular. The F3II carcinoma and mouse biologi-
cal individualities and the individual response of each 
Table 7 Mean ± mean standard error of parameters obtained from fitting of  TGK2 for direct current treated male groups
* 0.019±0.0005, **0.013±0.0003 and +0.007±0.0001.  TGK2 was the second part of the direct current perturbed F3II tumor growth kinetic. The variable  i0 was the 
polarization current and  ei0 its estimation error. The variable γ was the exponential decay ratio and  eγ its estimation error. The maximum distance, root means square 
error, sum of squares of errors, standard error of the estimate, adjusted goodness-of-fit coefficient of multiple determination, predicted residual error sum of squares 
and multiple predicted residual sum error of squares were denoted by parameters  Dmax, RMSE, SSE, SE, r
2
a , PRESS and MPRESS (for m = 3), respectively. Legends of TG1-
M, TG2-M, TG3-M, TG4-M, TG5-M and TG6-M were defined in Experiment subsection
Parameters Experimental groups
TG1-M TG2-M TG3-M TG4-M TG5-M TG6-M
i0 (mA) 1842 ± 0.158 4.147 ± 0.186 1.495 ± 0.090 1.516 ± 0.075 4.333 ± 0.232 7.119 ± 1.084
i/i0 1.086 1.447 0.968 1.319 1.385 1.405
γ  (days−1) 13.197 ± 3.920 4.536 ± 0.769 7.526 ± 2.513 12.742 ± 6.769 27.890 ± 9.379 10.291 ± 2.321
ei0  (days
−1) 0.021 ± 0.003 0.032 ± 0.004 0.019 ± 0.000* 0.013 ± 0.000** 0.053 ± 0.009 0.094 ± 0.005
eγ  (days
−1) 0.009 ± 0.002 0.007 ± 0.000+ 0.008 ± 0.002 0.014 ± 0.009 0.256 ± 0.078 0.048 ± 0.007
SSE  (cm3) 0.649 ± 0.131 0.101 ± 0.033 0.221 ± 0.079 0.115 ± 0.052 0.068 ± 0.024 0.522 ± 0.268
SE  (cm3) 0.120 ± 0.003 0.041 ± 0.008 0.068 ± 0.013 0.040 ± 0.013 0.036 ± 0.009 0.082 ± 0.034
RMSE  (cm3) 0.116 ± 0.004 0.040 ± 0.008 0.066 ± 0.012 0.039 ± 0.013 0.034 ± 0.008 0.080 ± 0.033
PRESS  (cm3) 0.095 ± 0.040 0.008 ± 0.005 0.031 ± 0.012 0.017 ± 0.013 0.014 ± 0.007 0.103 ± 0.072




0.960 ± 0.035 0.794 ± 0.198 0.993 ± 0.003 0.997 ± 0.001 0.989 ± 0.006 0.996 ± 0.002
Dmax  (cm
3) 0.956 ± 0.038 0.992 ± 0.002 0.992 ± 0.003 0.085 ± 0.032 0.065 ± 0.015 0.182 ± 0.068
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mouse to EChT action may explain why different tumor 
sizes are observed at each instant of time. It is important 
to know that physiological ulceration is characteristic of 
this tumor histological variety, as reported in [10]. Fur-
thermore, fibrosis after EChT application is observed in 
previous studies [5, 6].
Tumor damages induced by DC cytotoxic action during 
and after EChT application are well documented in the 
literature [1–3, 15–18, 20]. Nevertheless, the induction 
of necrosis (around anode and cathode) and/or apopto-
sis (around anode) do not necessarily lead to a complete 
remission of the tumor. These irreversible damages and 
others are necessary conditions but not sufficient to 
reach this tumor response type after the application of 
EChT or any antitumor therapy. That is why, histological 
analysis to verify tumor damage is not performed in this 
study. CR of a tumor treated with EChT or any antitumor 
therapy may be reached by means of longitudinal stud-
ies that combine experimental and theoretical results to 
know in depth how these therapies influence on TGK. 
That is why, this study and [5] are carried out.
The average values of r2a close to one and the values 
close to zero of  eα,  eβ,  eγ,  ei0, SSE, SE, PRESS, MPRESS 
(for m = 3), RMSE and  Dmax confirm that the MGE is fea-
sible to describe experimental data of primary F3II mam-
mary carcinoma treated and not treated with DC for each 
gender and C-I, C-II and C-III. This finding may sug-
gest that the MGE is applicable to fit data of DC treated 
tumors with different values of i and  texp and any geom-
etry of electrode array  (MSNEIIc,  MSNEIInc and MPE).
In previous works, it has been suggested that EChT 
effectiveness increases for higher values of the (i/i0) ratio 
and lower value of γ [4–6]. Nevertheless, these works do 
not discuss how this effectiveness is affected when  texp 
and electrode array geometry are considered. Although 
 texp and electrode array geometry do not appear explic-
itly in the MGE, this study demonstrates that their influ-
ences on the F3II mammary carcinoma are implicit in 
the parameters  i0 and γ, which depend also on i and the 
tumor histological variety growing in the host. Con-
sequently, the (i/i0) ratio and parameters  a1 and  a2 also 
depend on  texp, electrode array geometry, tumor histo-
logical variety and type of host.
Results observed in TG2-F and TG2-M demonstrate 
that higher (i/i0) ratio, longer  texp and lower value of γ 
correspond to the greater growth delay of primary F3II 
mammary carcinoma. The lowest value of γ corresponds 
to the longest duration of the net anti-tumor effect of 
the EChT induced in the tumor [4–6] and long  texp is 
suggested in [5]. Additionally, this study indirectly con-
firms the hypothesis that the complete response of a solid 
tumor is reached from a threshold value of the (i/i0) ratio, 
named (i/i0)u. This may be argued because the complete 
response of the primary F3II mammary carcinoma after 
EChT application is not observed for the condition (i/
i0) < (i/i0)u. González et al. [5] report experimentally that 
(i/i0)u = 1.50 for this tumor histological variety. These 
findings demonstrate the good correspondence between 
the theoretical and experimental results and suggest 
that the primary F3II mammary carcinoma should be 
treated with EChT for long  texp and lower i. Addition-
ally, they confirm the existence of (i/i0)u and corroborate 
the hypothesis that the more aggressive the tumor is the 
more sensitive to EChT. On the other hand, although 
tumor complete remission is not reached, significant 
delay of tumor growth observed in TG2-F and TG2-M 
may indicate that EChT constitutes a feasible option for 
highly aggressive and metastatic primary tumors, as in 
[5].
Except TG2-F and TG2-M, larger mean standard errors 
of the tumor volume may explain why treated groups and 
their respective control groups do not differ significantly 
when they are compared at each time instant. The lat-
ter is observed for each gender and other experimental 
groups. An explanation to these larger mean standard 
errors is given in [5]. The individual behavior of each 
BALB/c/Cenp mouse bearing the primary F3II mam-
mary carcinoma observed in both control and treated 
groups justifies, in part, why the control group is not the 
true reference for treated groups, in agreement with [5, 
21]. Consequently, the real control for an EChT treated 
tumor is the mouse itself before therapy application. That 
is why, the analysis of TGK should be made individually 
in the same mouse, bearing the same tumor type, before 
and after EChT application, as in [5].
Calzado et al. [9] report theoretically that all configura-
tions of MPE induce a tumor damage percentage ≥ 80% 
whereas  MSNEIIc and  MSNEIInc ≤ 30%. In contrast, this 
work shows that there are no significant differences in 
TGK when MPE and  MSNEIIc are used, except for TG2-F 
and TG2-M (C-II and  texp = 20  min). This experimental 
finding is observed for both genders. Consequently, two 
suggestions arise: MPE and  MSNEIIc may be indistinctly 
used for cancer under EChT application and  texp influ-
ences more on TGK delay than C-II, corroborating that 
larger  texp and low DC doses should be recommended for 
highly aggressive and metastatic primary tumors.
The experimental fact that C-II does not induce high 
tumor damage percentage, as predicted theoretically in 
[9], may be explained because the F3II mammary car-
cinoma is a highly aggressive and metastatic primary 
tumor [5, 10]. It is documented that the high aggressive-
ness of a solid malignant tumor is due to its high intra-
tumor heterogeneity and anisotropy that influence on the 
evolution and metastasis of the cancer, therapy resist-
ance and the immune response [22–24]. Intra-tumor 
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heterogeneity and anisotropy of this tumor histological 
variety are confirmed in [5] and in this study. Addition-
ally, these two aspects are not included in the simulations 
made in [9], another reason that explains differences 
between these theoretical and experimental results. On 
the other hand, intra-tumor heterogeneity has been also 
linked to the stochastic spatial of cancer growth [25]. 
This stochastic behavior of the tumor growth is a direct 
consequence of the large biological individuality of DC 
treated and untreated tumors, as confirmed in this study 
and in [4–6].
Calzado et al. [9] report that higher values of the tem-
perature and the heat generated by MPE influence more 
on the high tumor damage percentages than the electro-
chemical processes induced in the tumor by the geom-
etries of electrode arrays. In contrast, this study suggests 
that these two physical quantities do not provoke signifi-
cant delay on TGK in the experimental groups, in which 
C-II is used. We do not discard that the temperature 
and the heat induced in this tumor histological variety 
influence on unexpected EChT effectiveness for C-II, as 
predicted theoretically in [9]. This hypothesis may be jus-
tified because high values of these two physical quanti-
ties may induce an inflammatory process in the tumor. It 
has been documented that the inflammation induced in 
tumors is linked with their growth and metastasis [26]. 
Therefore, we should be very careful with the use of MPE.
Despite the most accepted antitumor mechanism 
of EChT is electrochemical [2, 16], acid and basic pH 
fronts that induce MPE overlap rapidly due to the small 
separation distance in each pair of electrodes. This rapid 
overlapping of acidic and basic pH fronts generated by 
MPE does not occur when the  MSNEIIc and  MSNEIInc 
are inserted into the tumor. Recently, Calzado et al. [17] 
conclude that the greater separation between electrodes 
induce the higher area of tissue destruction. Therefore, 
we do not affirm completely that MPE is better than 
 MSNEIIc and  MSNEIInc when EChT is used, in the cur-
rent mode [8] and voltage mode [27].
Although the results of this study and those described 
in [5] agree, some differences may be mentioned. Unlike 
[5], in this study, it is experimentally proved the MPE 
effectiveness on the primary F3II mammary carcinoma. 
Additionally, in it is reported how MPE and  MSNEIIc 
influence on MGE. This suggests that the effect induced 
by any geometry of electrode array on TGK may be eval-
uated by means of MGE. These results have no precedent 
in the literature. As a result, this work encourages to go 
deeper on how (i/i0)u and the parameter γ depend explic-
itly on  texp, electrode array geometry [MPE,  MSNEIIc or 
 MSNEIInc], tumor histological variety, host type, number 
of times that EChT is repeated and combination of EChT 
with any antitumor therapy.
The results of this study and those reported in [5, 8, 9, 
17, 18, 27] suggest that the growth delay of the primary 
F3II mammary carcinoma may be increased optimizing 
 MSNEIIc,  MSNEIInc and MPE geometries and/or com-
bining EChT with other physical therapies [15, 28] and/
or other antitumor therapies. For instance, a new ques-
tion arises: can MGE be used to fit tumor gowth kinetics 
treated with combined therapies (i.e., direct current and 
immunotherapy/chemotherapy)?
The aforementioned may be important to plan and per-
sonalize EChT in order to reach the complete remission 
or the stationary partial response (cancer can be turned 
into a controlled chronic disease) of any tumor histo-
logical variety growing in a specific host. This cannot be 
obtained if we focus separately in theoretical or experi-
mental results. That is why, we addresses our efforts to 
report works that integrate both results, as this study, 
which confirms that the knowledge and therapeutic of 
the cancer is in the frontier of oncology, mathematics, 
physics, biophysics and other sciences, as the results 
reported in [9, 14, 27, 29] suggest. In addition, this inte-
grated analysis of experimental results and those that 
provide mathematical modeling will ensure communica-
tion in the shortest time between basic and clinical sci-
ence and the proposal of an optimal personalized therapy.
Conclusions
In conclusion, the electrochemical therapy may be poten-
tially addressed to highly aggressive and metastic pri-
mary F3II murine mammary carcinoma and the modified 
Gompertz equation may be used to fit data of this direct 
current treated carcinoma. Additionally, electrochemi-
cal therapy effectiveness depends on the exposure time, 
geometry of multiple-electrodes and ratio between the 
direct current intensity applied and the polarization cur-
rent induced in the tumor.
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